Lyme Disease
Educational Resources


Featured Lyme Book

Pharmaceutical Mistake Leads to Recall of Prominent Antibiotic

SCOTTSDALE, Ariz. -Medicis today announced that the Company is voluntarily recalling lot numbers B080037 (Exp: 12/09) and B080038 (Exp: 12/09) of the antibiotic SOLODYNŽ (minocycline HCl, USP) Extended Release Tablets, 90 mg, 30-count bottles (NDC 99207-461-30). Medicis has received a report that one bottle in lot number B080037 contains AZASANŽ (azathioprine tablets) 75 mg (NDC 65649-231-51) instead of SOLODYNŽ (minocycline HCl, USP) Extended Release Tablets, 90 mg. AZASANŽ is an immuno-suppressive agent used in transplant patients to prevent kidney rejection and for the treatment of rheumatoid arthritis. Taking AZASANŽ instead of SOLODYNŽ presents a health hazard and safety risk to patients. Side effects associated with the use of AZASANŽ, particularly in the elderly, include mylosuppression (decrease in the number of red and white blood cells and platelets), infection, bleeding, chills, nausea, vomiting and diarrhea. Joint and muscle pain are also common side effects. Unanticipated interactions with other drugs may also lead to serious adverse events. SOLODYNŽ is manufactured by AAIPharma, Inc. under contract to Medicis. The two lots were manufactured during February 2008. The recall is limited to these lots, and ample supplies of SOLODYNŽ remain on the market.

Any inquiries related to this recall should be addressed to Stericycle Customer Service at 1-888-656-6381 with representatives available Monday through Friday, 8 a.m. to 11 p.m. EST. For any medical information inquiries or to report an adverse event related to this recall, contact Medicis at 1-800-900-6389 with representatives available 24 hours a day, 7 days a week.

Health care professionals may continue to prescribe the Medicis brand SOLODYNŽ.
This recall is being conducted in cooperation with the contract manufacturer of the products and with the knowledge of the FDA.

Any adverse reactions experienced with the use of this product, and/or quality problems, also may be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch.

SOLODYN is a registered trademark of Medicis Pharmaceutical Corporation. AZASAN is a registered trademark of AAIPharma, Inc. 

Thank You to Our Sponsors!

Entire site copyright 2008 by Public Health Alert, 
821 Sansome Drive, Arlington TX 76018

LEGAL NOTICE: All articles on this website are protected under U.S. Copyright laws. All articles belong to the authors and may not be copied, re-posted, forwarded or reprinted without the expressed written permission of the author. The information presented in this website and the Public Health Alert newspaper is for informational purposes only. No information should be considered medical advice. Any information provided should not be used to take the place of advice from your personal
physician or other professional. Links to other sites are provided for ease of research. Information on those sites represents the opinion of those who publish the sites and is not necessarily that of the Public Health Alert.